Genetic testing can pick out men at increased risk of testicular cancer

June 12, 2017, Institute of Cancer Research
Cancer cell during cell division. Credit: National Institutes of Health

Testing for large numbers of genetic changes can identify men with over a 10-fold increased risk of testicular cancer, a new study shows.

Researchers found that testing for newly identified genetic factors along with others found in their previous studies could pick out men at increased risk, who might potentially benefit from monitoring or preventative treatment.

Scientists at The Institute of Cancer Research, London, studied the DNA of 30,000 men and identified 19 new genetic changes associated with the disease.

Testing these alongside previously identified genetic factors - covering a total of 44 genetic markers - picked out 1 per cent of men at highest risk of the disease.

These men had a 7 per cent lifetime risk of developing testicular cancer - a risk 14 times higher than the 0.5 per cent risk in the general male population.

The findings could in future lead to the development of clinical tests to identify men at highest risk so they could be offered preventative treatment or monitoring.

The study, funded by the Movember Foundation and published today (Monday) in Nature Genetics, also uncovered clues about how risk genes are activated and pointed to potential targets for new treatments.

Testicular cancer is the most common cancer in young men. Treatment with platinum chemotherapy is usually successful but some men do not respond, and as men are typically diagnosed in their twenties or thirties, they may have to live with long term side-effects of chemotherapy for many decades.

The team at The Institute of Cancer Research (ICR) compared DNA from 7,319 men with testicular cancer with that of 23,082 without the disease from three separate studies.

By reading the DNA code of these men in detail, the researchers were able to pick out 'single letter' changes in their DNA that increased their risk of developing testicular cancer.

Scientists can now explain a third of the inherited risk of testicular cancer, after taking the total number of genetic factors linked to the disease to 44 in total.

In their study, the researchers also looked in detail at what happened inside cells that caused the newly discovered genetic errors to lead to cancer.

They discovered that many of the gene changes increase testicular cancer risk by interfering with the way gene activity is controlled in the cell.

The genes that seem to be particularly affected in testicular cancer are those that are normally involved in stabilising chromosomes inside cells, or that interact with the well-known cancer gene KIT.

Study leader Dr Clare Turnbull, Senior Researcher in Genetics and Epidemiology at the ICR, said:

"Our study has almost doubled the number of DNA variations linked to increased risk of developing testicular cancer and advanced our ability to use genetics to predict disease in healthy men.

"Although we are making good headway, there are more genetic changes that affect risk still to be found. Further studies are needed to understand how these interact over time to influence the biology of the cell and lead to development of cancer."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"Large-scale genetics studies, such as this one, are a crucial part of our mission to defeat cancer. The more we understand about the genetics of cancer, the better we can pick out people at most risk before they develop the disease.

"As well as picking out men at highest risk of testicular cancer, our new study also looks at the biology of the disease - at what drives cells to become cancerous. This should narrow the search for therapeutic targets and help researchers create new treatments for those men who stop responding to platinum chemotherapy."

Paul Villanti, Director of Programmes, the Movember Foundation, said:

"This study has made significant progress in identifying men at increased risk of , and sets up pathways to the new treatments that are so desperately needed to save men for whom current treatments are unsuccessful.

"Testicular typically strikes at young men in their prime, and progress in this field promises huge benefits to these individuals and their families. As ever, we are incredibly grateful to the donors and supporters of the Movember campaign - your funds are creating a brighter future for men's health."

Explore further: Genetic testing could identify men at a 10-fold increased risk of testicular cancer

More information: "Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor," Nature Genetics (2017). DOI: 10.1038/ng.3896

Related Stories

Genetic testing could identify men at a 10-fold increased risk of testicular cancer

October 27, 2015
A new study of more than 25,000 men has uncovered four new genetic variants associated with increased risk of testicular cancer.

Nearly half of testicular cancer risk comes from inherited genetic faults

September 9, 2015
Almost half of the risk of developing testicular cancer comes from the DNA passed down from our parents, a new study reports.

Major study links gene to drug resistance in testicular cancer

January 22, 2015
A major research study has uncovered several new genetic mutations that could drive testicular cancer - and also identified a gene which may contribute to tumours becoming resistant to current treatments.

Low testosterone after testicular cancer is common, linked to chronic health problems

June 5, 2017
In a large study, 38 percent of 491 testicular cancer survivors had low testosterone levels, known as hypogonadism. Compared to survivors with normal testosterone levels, survivors with low testosterone were more likely to ...

Men who have had testicular cancer are more likely to develop prostate cancer

February 24, 2015
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 ...

Recommended for you

Resetting the epigenetic balance for cancer therapy

May 22, 2018
Though mutations in a gene called MLL3 are common across many types of cancers, their relationship to the development of the disease has been unclear. Now, a Northwestern Medicine study has identified an epigenetic imbalance ...

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

Bladder cancer model could pave the way for better drug efficacy studies

May 21, 2018
Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients ...

Breath test breakthrough for early diagnosis of oesophageal and gastric cancer

May 18, 2018
A breath test can successfully detect oesophageal and gastric cancer and could be used as a first-line test for patients, say researchers.

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas

May 18, 2018
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.